Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Svea Ekonomi in connection with investment in Stidner Complete
Mandate

Vinge advises Svea Ekonomi in connection with investment in Stidner Complete

July 13, 2017

Vinge has advised Svea Ekonomi AB (”Svea”) in connection with its investment in the innovative e trading solution company Stidner Complete AB.

The investment has been performed as a directed issue of new shares to Svea Ekonomi.

Stidner provides its customers with a complete cash management system, freight booking, packaging system and customer portal for e trading. Svea Ekonomi is a financial group with operations in several European countries which offers administrative and financial solutions.

Vinge’s team consisted of associates Alex Miler and Lionardo Ojeda.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024